Treatment of Primary Sclerosing Cholangitis with Concurrent Autoimmune Hepatitis (AIH)

This protocol applies to patients with primary sclerosing cholangitis (PSC) who carry a concurrent diagnosis of autoimmune hepatitis (AIH) — an overlap presentation in which both conditions are active and require coordinated management.

The co-existence of AIH significantly shapes treatment priorities. When manifestations of autoimmune hepatitis are predominant, management must address this component directly, following guidelines established specifically for AIH.

The cornerstone of management in this overlap scenario involves immunosuppressive therapy directed by recognised AIH guidelines. Specific agents, sequencing, and criteria for initiation are defined in the full structured protocol —

Complete regimen, clinical decision points, and escalation criteria are available in the full protocol →